Navigation Links
U.S. District Court Order Maintains Patent Exclusivity for Lilly's Cymbalta
Date:4/27/2011

INDIANAPOLIS, April 27, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana has issued an order that prohibits the remaining defendants in the Cymbalta® (duloxetine hydrochloride) patent litigation from selling a generic duloxetine product in the United States during the term of the Cymbalta compound patent. The patent provides protection for Cymbalta until at least June of 2013.  

The order came in the case of Eli Lilly and Company v. Wockhardt Limited, et al. The Court had initially entered final judgment against Wockhardt on March 21, 2011.  As part of today's Court order, the defendants are further required to notify the Food and Drug Administration that they are no longer seeking approval for a generic duloxetine product during the patent term. In light of the parties' stipulation to the Court's order, the litigation has been dismissed and no appeal is possible.  

"We are very pleased with the District Court's order that effectively maintains U.S. exclusivity for Cymbalta throughout its patented life," said Robert A. Armitage, senior vice president and general counsel for Lilly. "Protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve. These rights provide assurances of market exclusivity that help support the development of the next generation of innovative medicines to treat unmet medical needs."

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  C-LLY

This release contains forward-looking statements regarding the U.S. Cymbalta patent litigation. These statements are based on management's current expectations but actual results may differ materially. Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission.

Cymbalta® (duloxetine hydrochloride, Lilly)

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
2. Watson Announces Favorable District Court Ruling in Generic Fentora® Patent Suit
3. Watson Announces Favorable District Court Ruling in Generic Mucinex® Patent Suit
4. Sensipar® Patents Upheld By District Court
5. Winner Medical Honored with Shenzhen Baoan District Quality Award
6. U.S. District Court Rules from Bench in Lillys Favor, Confirms Validity of Alimta Patent
7. German District Court Finds RENASYS™ GO NPWT System Non-infringing
8. Capital District Health Authority and IWK Health Centre to Implement Anesthesia Information Management System
9. Renhuang Wins Bid to Supply All-Natural Products to Guangzhou Military District
10. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
11. McDonald Hopkins Law Firm Alert: Recent Court of Appeals Decision Highlights the Need to Properly Define the Role of Sales Representatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... June 9, 2017 AirXpanders, Inc. (ASX: AXP) ... the design, manufacture, sale and distribution of the AeroForm® ... progress of its commercial roll-out in the ... more than one hundred (100) medical institutions and health ... offers a needle-free alternative for women who choose reconstructive ...
(Date:6/8/2017)... 8, 2017  StatLab Medical Products ("StatLab" ... manufacturer of diagnostic supplies for the anatomic ... & Company LP ("Cressey & Company"), a ... growth-focused investment in the Company. Cressey & ... from selling shareholder, Prairie Capital, L.P., with ...
(Date:6/5/2017)... 2017 The Cincinnati location ... Inc. (NYSE: DPLO), has been awarded a Top Workplaces ... Results are based on an employee survey administered by ... workplace improvement. The survey measures several aspects of workplace culture, ... ...
Breaking Medicine Technology:
(Date:6/23/2017)... , ... June 23, 2017 , ... The Military Officers ... nominee for deputy secretary of Veterans Affairs, retired Marine Col. Thomas G. Bowman. , ... , Bowman brings an intimacy with the issues and challenges veterans face ...
(Date:6/23/2017)... ... June 23, 2017 , ... Goodcents Deli Fresh Subs today announced the opening ... 4210 SW 21st St. Topeka, Kan. 66604 (near 21st and Gage). It is owned ... owns three other locations in the Topeka and Bonner Springs, Kan. area. , ...
(Date:6/23/2017)... ... ... 21 Middle East and South Asia Leaders Selected as Eisenhower Fellows , ... society in 11 countries across the Middle East and South Asia to embark on ... knowledge and ideas with the leading minds in their fields. , For the ...
(Date:6/23/2017)... ... ... American Farmer, will feature Chr. Hansen, Inc (CHR Hansen) in an upcoming episode ... Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for more info. ... 1874 after a groundbreaking discovery of how to industrialize enzymes. Rooted in science and ...
(Date:6/23/2017)... ... June 23, 2017 , ... All-Star Insurance, a family ... business clients throughout eastern Texas, is announcing the launch of a new charity drive ... cancer statistics in the United States reveal that an estimated 252, 710 new cases ...
Breaking Medicine News(10 mins):